Response of Diabetic Papillopathy to Intravitreal Bevacizumab

Abstract

Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy to intravitreal injection of bevacizumab (Avastin, Genentech Inc, San Francisco, California, USA), a humanized monoclonal antibody to vascular endothelial growth factor.

DOI: 10.4103/0974-9233.84056

Cite this paper

@inproceedings{AlDhibi2011ResponseOD, title={Response of Diabetic Papillopathy to Intravitreal Bevacizumab}, author={Hassan A. Al-Dhibi and A O Khan}, booktitle={Middle East African journal of ophthalmology}, year={2011} }